DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2017/0130247 A1 Dowen Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2017/0130247 A1 Dowen Et Al US 2017O 130247A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0130247 A1 DOWen et al. (43) Pub. Date: May 11, 2017 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ALTERING GENE EXPRESSION (60) Provisional application No. 62/234.770, filed on Sep. (71) Applicant: Whitehead Institute for Biomedical 30, 2015. Research, Cambridge, MA (US) Publication Classification (72) Inventors: Jill M. Dowen, Chapel Hill, NC (US); (51) Int. C. Zi Peng Fan, Waltham, MA (US); CI2N 15/90 (2006.01) Denes Hnisz. Cambridge, MA (US); (52) U.S. C. Tong Ihn Lee, Somerville, MA (US); CPC ........ CI2N 15/907 (2013.01); C12N 2800/80 Richard A. Young, Boston, MA (US) (2013.01) (21) Appl. No.: 15/282,905 (57) ABSTRACT Provided herein are improved compositions and methods for (22) Filed: Sep. 30, 2016 the directed control of gene expression. Patent Application Publication May 11, 2017. Sheet 1 of 43 US 2017/O130247 A1 Figare i i00,000 Chronosoines: {},{}{}{} {{E} opologicaily s Associating otains {{ Gene loops Naceosonies Patent Application Publication May 11, 2017. Sheet 2 of 43 US 2017/O130247 A1 Figure : S. Kic Enhanceti 4% Promoter 3% Polyconi S9, the Patent Application Publication May 11, 2017. Sheet 3 of 43 US 2017/O130247 A1 Figure Reads {-aight 4{{ } {{}{.{{}{} Unique PETs 9,442.89) PET peaks & & ... & & & ...& 8...&... & f68.88: } interactions annig PET peaks High-coficience: iteraction agg FE peaks (empirical FER<-0.0i, 3. --- "C" ·&&.8.xxx................ oxoi.8°8'''88's'ss's48&S SMC “tookook os---to do OSN &: : or Super-enhance :::: 88: Patent Application Publication May 11, 2017. Sheet 5 of 43 US 2017/O130247 A1 Figar: 2 Hi-C interaction frequencies opoiogicaiy Associating 8) nat: High-confidence iteraction * Genes Patent Application Publication May 11, 2017. Sheet 6 of 43 US 2017/O130247 A1 Figure 2 3. 8 o 3. & 8. 40 s 3 & O is: w88:3 (C. 2% 88% beyond within TAS A38 Patent Application Publication May 11, 2017. Sheet 7 of 43 US 2017/O130247 A1 Figare 2 3. S E. High-confidence iteraction &: '8; 8.3388& 8 £3 xxiiciaty 8:33rtiary Patent Application Publication May 11, 2017. Sheet 8 of 43 US 2017/O130247 A1 Figare 3 gx38xicaisy &883::::::g. 88ai & s ; : . i ii. - - - - - - - - - - - - - - - - -& xxx s'. 8.8 3 s : & {{xxixg:kaiy &ssocia: 3883i: &::::::: 8: ki::ity (388 Patent Application Publication May 11, 2017 Sheet 9 of 43 US 2017/O130247 A1 38 v. 2: 43 Patent Application Publication May 11, 2017. Sheet 10 of 43 US 2017/0130247 A1 : 8 8. 8. : 33:888sy d 38.3888; Patent Application Publication May 11, 2017 Sheet 11 of 43 US 2017/O130247 A1 Patent Application Publication May 11, 2017. Sheet 12 of 43 US 2017/0130247 A1 Figure 4 A. 3888-8::::3::ce. Eg: . Patent Application Publication May 11, 2017. Sheet 13 of 43 US 2017/0130247 A1 Figure 4 83 & &:::::::::::::::::::::::::::::::::: 3:33 s 8-8-- 88:88. Patent Application Publication May 11, 2017 Sheet 14 of 43 US 2017/O130247 A1 Figare 4 8. f 3:38:8 8 ::::::::: ;----~--~~~~~~*~*~~~~~~~~~~~~****~~~~~~~~~~*** Patent Application Publication May 11, 2017. Sheet 15 of 43 US 2017/0130247 A1 Figure 4 M 8:38-:388:88): 38::::::::: d Patent Application Publication May 11, 2017. Sheet 16 of 43 US 2017/0130247 A1 Figure 4 &-88::::::: 3:3: Patent Application Publication May 11, 2017. Sheet 17 of 43 US 2017/0130247 A1 Figure 5 A. *:::::::::::::::::::::: » x&g::::::::x: 8x8:3388:8: i: 888 {3888 Patent Application Publication May 11, 2017. Sheet 18 of 43 US 2017/0130247 A1 Figare 5 ---------------------------------- 88:3: 8:3 Patent Application Publication May 11, 2017. Sheet 19 of 43 US 2017/0130247 A1 Figure 5 3. r: stews p boundary bo::ciary Patent Application Publication May 11, 2017. Sheet 20 of 43 US 2017/0130247 A1 Figares $388:383 3:38 Y s 3. 88: s - Patent Application Publication May 11, 2017. Sheet 21 of 43 US 2017/0130247 A1 Figare 5 :: S8.s: 8s: Patent Application Publication May 11, 2017. Sheet 22 of 43 US 2017/0130247 A1 i Patent Application Publication May 11, 2017 Sheet 23 of 43 US 2017/O130247 A1 Patent Application Publication May 11, 2017. Sheet 25 of 43 US 2017/O130247 A1 Figtre 7 (Figare Si No.ººººººººººººººº! 7% Enhancer Patent Application Publication May 11, 2017. Sheet 26 of 43 US 2017/0130247 A1 Figure 7 Figare Si Patent Application Publication May 11, 2017. Sheet 27 of 43 US 2017/0130247 A1 Figarei (Figure Si) g 38:38::::::::::: P a. 838-3. a m . s4 &::*-8 & oc or - 2 2 88-8 - K r 88. K3 & 38.x: Rep; on Seif-tigation E. count 3'er kb bins (r.p.k.a. } x-, s 8 8. 8: Patent Application Publication May 11, 2017. Sheet 28 of 43 US 2017/0130247 A1 Figre 7 (Figure Si Non-chrei PE {Chineric PET a: - 3338. : & 38. 38 33. :8 Geronic 8ian Genomic span it of PETs per interaction Patent Application Publication May 11, 2017. Sheet 29 of 43 US 2017/0130247 A1 Figure 7 (Figure S. G. interactions High-confidence interactions {erapiricai FOR <30.8, 3:Es) 82% 8% - 39% ter-chronixsotia 33-chroniososia tier-chronosoina intra-chioiosonkai Saiitiation of the Sw: , Ch;A-PET Library Fraction of PETs Reiative to Current ataset Size Patent Application Publication May 11, 2017. Sheet 30 of 43 US 2017/0130247 A1 Figare 8 (iigstre S2) 3::::::::::::::: &x:3:33:33:3:38 ix::c:gic:y 8888ciatig :::::::::::: :::::::::: Patent Application Publication May 11, 2017. Sheet 31 of 43 US 2017/0130247 A1 Figure 8 Figtre S2) 33:::::: *:::::::38: $23888; 8: 83. 2333} :::::: 3:3: & 8:8::::::::::8 88:38-3:8:::::::::: 3i. 23:3: Patent Application Publication May 11, 2017. Sheet 32 of 43 US 2017/0130247 A1 Figs re 9 (Figtse S3} seases 8:x: 3:33:8:33:::::::: Six:8: & ...wik.... ...wikowow. & k sax Patent Application Publication May 11, 2017. Sheet 33 of 43 US 2017/0130247 A1 Figare 9 (Figure S3) & 838:33:3:3: M 8:88-8383:38:338:3 &: kx sixko www.s. S3888-8:33:3: Ex:3: i:88s &:s:x::::::::::::::::::::: to so &:83-8:33:30:8: 3888... : Patent Application Publication May 11, 2017. Sheet 34 of 43 US 2017/0130247 A1 Figure 9 (Figure S3 mem &:g::::::::::::::88: 3:3:38 Patent Application Publication May 11, 2017. Sheet 35 of 43 US 2017/0130247 A1 Figare 9 (Figure S3 ::::::::::::::::::y;&&8:::::::::::33:8: &::::::::::::::::ce: 3:38: Patent Application Publication May 11, 2017. Sheet 36 of 43 US 2017/0130247 A1 Figure 8 (Figure S4 8:88-8:38& $3838 3C-888&gatx 3:23:8388 : {38: ra sig3:8:8; 88-388-388 33 Patent Application Publication May 11, 2017. Sheet 37 of 43 US 2017/0130247 A1 Figure 8 (Figure S4 win $:383-8:38:3: 3883: -j-i-m-i-. - s 38-8errogated 8:3:33:38 3.33. :::::::S:8: 3x38:38 Patent Application Publication May 11, 2017. Sheet 38 of 43 US 2017/0130247 A1 Figarei (Figure S4 wix type ESC 3C 3 trix-388-38. sSS s *::::::::::::::y :::::::::::: k:gixxist: 88:88: ::::::::: 3:x: Patent Application Publication May 11, 2017. Sheet 39 of 43 US 2017/0130247 A1 Figare ii (Figre S5) 3::::::::::::::::::y 8888c:::::::::33::::::: t 38 ---........................ Sssssssssssssss ii; Patent Application Publication May 11, 2017. Sheet 40 of 43 US 2017/0130247 A1 Figare (Fig are S5) 3:388x338; 8.388x333i: 38883: hoto-8: $8ycory: s38::::::: - X::::::::::: 3:8338c:38;33 8:::::::::::::::::::38:8w Patent Application Publication May 11, 2017. Sheet 41 of 43 US 2017/0130247 A1 Figure ii (Figure S5) x:3:38:8: Patent Application Publication May 11, 2017. Sheet 42 of 43 US 2017/0130247 A1 Figtre i (Figare S5) ::::::::::::::::::y 8$88:a::g .3388: $3::::::::: 33;x:::::::::::::: *$88:::::::::::::38:8 ::::::::::::8& Patent Application Publication & $$$84 US 2017/O 130247 A1 May 11, 2017 COMPOSITIONS AND METHODS FOR 2012: Filippova et al., 2014; Gibcus and Dekker, 2013; ALTERING GENE EXPRESSION Naumova et al., 2013: Nora et al., 2012). 0009 TADs, also known as topological domains, are CROSS-REFERENCE TO RELATED defined by DNA-DNA interaction frequencies, and their APPLICATION(S) boundaries are regions across which relatively few DNA DNA interactions occur (Dixon et al., 2012: Nora et al., 0001. This application claims the benefit of U.S. Provi 2012). TADs average 0.8 Mb, contain approximately seven sional Application No. 62/234,770, filed Sep. 30, 2015. The protein-coding genes, and have boundaries that are shared entire teachings of the above application is incorporated by the different cell types of an organism (Dixon et al., 2012: herein by reference. Smallwood and Ren, 2013). The expression of genes within aTAD is somewhat correlated, and thus some TADs tend to GOVERNMENT SUPPORT have active genes and others tend to have repressed genes 0002 This invention was made with government support (Cavalli and Misteli, 2013; Gibcus and Dekker, 2013: Nora under Grant Number HG002668 awarded by the National et al., 2012). Institutes of Health. The government has certain rights in the 0010 Gene loops and other structures within TADs are invention. thought to reflect the activities of transcription factors (TFs), cohesin, and CTCF (Baranello et al., 2014: Gorkin et al., FIELD OF THE INVENTION 2014; Phillips-Cremins et al., 2013: Seitan et al., 2013; Zuin et al., 2014). The structures within TADs include cohesin 0003. The present invention generally relates to methods associated enhancer-promoter loops that are produced when of selectively altering gene expression within, for example, enhancer-bound TFs bind cofactors such as Mediator that, in insulated neighborhoods formed by the looping of two turn, bind RNA polymerase II at promoter sites (Lee and CTCF interaction sites occupied by cohesion.
Load more

Recommended publications
  • Analysis of Gene Expression Data for Gene Ontology
    ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION A Thesis Presented to The Graduate Faculty of The University of Akron In Partial Fulfillment of the Requirements for the Degree Master of Science Robert Daniel Macholan May 2011 ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION Robert Daniel Macholan Thesis Approved: Accepted: _______________________________ _______________________________ Advisor Department Chair Dr. Zhong-Hui Duan Dr. Chien-Chung Chan _______________________________ _______________________________ Committee Member Dean of the College Dr. Chien-Chung Chan Dr. Chand K. Midha _______________________________ _______________________________ Committee Member Dean of the Graduate School Dr. Yingcai Xiao Dr. George R. Newkome _______________________________ Date ii ABSTRACT A tremendous increase in genomic data has encouraged biologists to turn to bioinformatics in order to assist in its interpretation and processing. One of the present challenges that need to be overcome in order to understand this data more completely is the development of a reliable method to accurately predict the function of a protein from its genomic information. This study focuses on developing an effective algorithm for protein function prediction. The algorithm is based on proteins that have similar expression patterns. The similarity of the expression data is determined using a novel measure, the slope matrix. The slope matrix introduces a normalized method for the comparison of expression levels throughout a proteome. The algorithm is tested using real microarray gene expression data. Their functions are characterized using gene ontology annotations. The results of the case study indicate the protein function prediction algorithm developed is comparable to the prediction algorithms that are based on the annotations of homologous proteins.
    [Show full text]
  • New Approaches to Functional Process Discovery in HPV 16-Associated Cervical Cancer Cells by Gene Ontology
    Cancer Research and Treatment 2003;35(4):304-313 New Approaches to Functional Process Discovery in HPV 16-Associated Cervical Cancer Cells by Gene Ontology Yong-Wan Kim, Ph.D.1, Min-Je Suh, M.S.1, Jin-Sik Bae, M.S.1, Su Mi Bae, M.S.1, Joo Hee Yoon, M.D.2, Soo Young Hur, M.D.2, Jae Hoon Kim, M.D.2, Duck Young Ro, M.D.2, Joon Mo Lee, M.D.2, Sung Eun Namkoong, M.D.2, Chong Kook Kim, Ph.D.3 and Woong Shick Ahn, M.D.2 1Catholic Research Institutes of Medical Science, 2Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul; 3College of Pharmacy, Seoul National University, Seoul, Korea Purpose: This study utilized both mRNA differential significant genes of unknown function affected by the display and the Gene Ontology (GO) analysis to char- HPV-16-derived pathway. The GO analysis suggested that acterize the multiple interactions of a number of genes the cervical cancer cells underwent repression of the with gene expression profiles involved in the HPV-16- cancer-specific cell adhesive properties. Also, genes induced cervical carcinogenesis. belonging to DNA metabolism, such as DNA repair and Materials and Methods: mRNA differential displays, replication, were strongly down-regulated, whereas sig- with HPV-16 positive cervical cancer cell line (SiHa), and nificant increases were shown in the protein degradation normal human keratinocyte cell line (HaCaT) as a con- and synthesis. trol, were used. Each human gene has several biological Conclusion: The GO analysis can overcome the com- functions in the Gene Ontology; therefore, several func- plexity of the gene expression profile of the HPV-16- tions of each gene were chosen to establish a powerful associated pathway, identify several cancer-specific cel- cervical carcinogenesis pathway.
    [Show full text]
  • Spatial Chromatin Architecture Alteration By
    Sadowski et al. Genome Biology (2019) 20:148 https://doi.org/10.1186/s13059-019-1728-x RESEARCH Open Access Spatial chromatin architecture alteration by structural variations in human genomes at the population scale Michal Sadowski1,2, Agnieszka Kraft1,3, Przemyslaw Szalaj1,4,5, Michal Wlasnowolski1,3, Zhonghui Tang6, Yijun Ruan7* and Dariusz Plewczynski1,3* Abstract Background: The number of reported examples of chromatin architecture alterations involved in the regulation of gene transcription and in disease is increasing. However, no genome-wide testing has been performed to assess the abundance of these events and their importance relative to other factors affecting genome regulation. This is particularly interesting given that a vast majority of genetic variations identified in association studies are located outside coding sequences. This study attempts to address this lack by analyzing the impact on chromatin spatial organization of genetic variants identified in individuals from 26 human populations and in genome- wide association studies. Results: We assess the tendency of structural variants to accumulate in spatially interacting genomic segments and design an algorithm to model chromatin conformational changes caused by structural variations. We show that differential gene transcription is closely linked to the variation in chromatin interaction networks mediated by RNA polymerase II. We also demonstrate that CTCF-mediated interactions are well conserved across populations, but enriched with disease-associated SNPs. Moreover, we find boundaries of topological domains as relatively frequent targets of duplications, which suggest that these duplications can be an important evolutionary mechanism of genome spatial organization. Conclusions: This study assesses the critical impact of genetic variants on the higher-order organization of chromatin folding and provides insight into the mechanisms regulating gene transcription at the population scale, of which local arrangement of chromatin loops seems to be the most significant.
    [Show full text]
  • An Investigation Into the Genetic Architecture of Multiple System Atrophy and Familial Parkinson's Disease
    An investigation into the genetic architecture of multiple system atrophy and familial Parkinson’s disease By Monica Federoff A thesis submitted to University College London for the degree of Doctor of Philosophy Laboratory of Neurogenetics, Department of Molecular Neuroscience, Institute of Neurology, University College London (UCL) 2 I, Monica Federoff, confirm that the work presented in this thesis is my own. Information derived from other sources and collaborative work have been indicated appropriately. Signature: Date: 09/06/2016 3 Acknowledgements: When I first joined the Laboratory of Neurogenetics (LNG), NIA, NIH as a summer intern in 2008, I had minimal experience working in a laboratory and was both excited and anxious at the prospect of it. From my very first day, Dr. Andrew Singleton was incredibly welcoming and introduced me to my first mentor, Dr. Javier Simon- Sanchez. Within just ten weeks working in the lab, both Dr. Singleton and Dr. Simon- Sanchez taught me the fundamental skills in an encouraging and supportive environment. I quickly got to know others in the lab, some of whom are still here today, and I sincerely appreciate their help with my assimilation into the LNG. After returning for an additional summer and one year as an IRTA postbac, I was honored to pursue a PhD in such an intellectually stimulating and comfortable environment. I am so grateful that Dr. Singleton has been such a wonderful mentor, as he is not only a brilliant scientist, but also extremely personable and approachable. If I inquire about meeting with him, he always manages to make time in his busy schedule and provides excellent guidance and mentorship.
    [Show full text]
  • Myopia in African Americans Is Significantly Linked to Chromosome 7P15.2-14.2
    Genetics Myopia in African Americans Is Significantly Linked to Chromosome 7p15.2-14.2 Claire L. Simpson,1,2,* Anthony M. Musolf,2,* Roberto Y. Cordero,1 Jennifer B. Cordero,1 Laura Portas,2 Federico Murgia,2 Deyana D. Lewis,2 Candace D. Middlebrooks,2 Elise B. Ciner,3 Joan E. Bailey-Wilson,1,† and Dwight Stambolian4,† 1Department of Genetics, Genomics and Informatics and Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, United States 2Computational and Statistical Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore, Maryland, United States 3The Pennsylvania College of Optometry at Salus University, Elkins Park, Pennsylvania, United States 4Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States Correspondence: Joan E. PURPOSE. The purpose of this study was to perform genetic linkage analysis and associ- Bailey-Wilson, NIH/NHGRI, 333 ation analysis on exome genotyping from highly aggregated African American families Cassell Drive, Suite 1200, Baltimore, with nonpathogenic myopia. African Americans are a particularly understudied popula- MD 21131, USA; tion with respect to myopia. [email protected]. METHODS. One hundred six African American families from the Philadelphia area with a CLS and AMM contributed equally to family history of myopia were genotyped using an Illumina ExomePlus array and merged this work and should be considered co-first authors. with previous microsatellite data. Myopia was initially measured in mean spherical equiv- JEB-W and DS contributed equally alent (MSE) and converted to a binary phenotype where individuals were identified as to this work and should be affected, unaffected, or unknown.
    [Show full text]
  • Epigenetics Bladder Cancer
    Published OnlineFirst March 3, 2016; DOI: 10.1158/2159-8290.CD-RW2016-040 RESEARCH WATCH Bladder Cancer Major finding: CDH1 mutations are Approach: Plasmacytoid variant tumors Impact: Plasmacytoid variant tumors specific to, and occur in the majority of, were molecularly characterized using are distinguishable from nonvariant plasmacytoid variant bladder cancers. whole-exome and targeted sequencing. bladder cancers by CDH1 mutations. PLASMACYTOID VARIANT BLADDER CANCERS HARBOR CDH1 MUTATIONS Bladder cancers have a large range of variant mor- was similar to lobular breast carcinoma and diffuse phologies, and tumors with wholly variant histolo- gastric carcinoma, both of which also have frequent gies exhibit worse survival rates. Variant histology CDH1 mutations. Patients with plasmacytoid vari- bladder cancers were not included in The Cancer ant cancer had a poorer survival rate, increased inci- Genome Atlas (TCGA), and, thus, the molecular dence of recurrence, and an increased incidence of events underlying these tumors remain poorly peritoneal spread compared to patients with other understood. Al-Ahmadie, Iyer, Lee, and colleagues types of bladder cancer. To determine if loss of used whole-exome and targeted sequencing to char- E-cadherin contributed to the aggressive phenotype, acterize plasmacytoid bladder cancer, an aggressive histologic CDH1 was deleted by CRISPR/Cas9 in two urothelial carci- variant cancer. Whole-exome sequencing of six plasmacytoid noma cell lines. CDH1 loss resulted in increased migration, variant bladder tumors revealed truncating somatic muta- suggesting that loss of E-cadherin may result in the increased tions in cadherin 1 (CDH1), which encodes E-cadherin, in all invasiveness of plasmacytoid variant tumors. These fi ndings of the tumors, whereas there were no CDH1-truncating muta- indicate that plasmacytoid variant bladder cancers are charac- tions in the 127 bladder cancers in TCGA.
    [Show full text]
  • Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories
    Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002)
    [Show full text]
  • WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, C12Q 1/68 (2018.01) A61P 31/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12Q 1/70 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2018/056167 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 16 October 2018 (16. 10.2018) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/573,025 16 October 2017 (16. 10.2017) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (71) Applicant: MASSACHUSETTS INSTITUTE OF MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TECHNOLOGY [US/US]; 77 Massachusetts Avenue, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Cambridge, Massachusetts 02139 (US).
    [Show full text]
  • Downregulation of RAI14 Inhibits the Proliferation
    Journal of Cancer 2019, Vol. 10 6341 Ivyspring International Publisher Journal of Cancer 2019; 10(25): 6341- 6348. doi: 10.7150/jca.34910 Research Paper Downregulation of RAI14 inhibits the proliferation and invasion of breast cancer cells Ming Gu1, Wenhui Zheng2, Mingdi Zhang3, Xiaoshen Dong1, Yan Zhao1, Shuo Wang1, Haiyang Jiang1, Lu Liu1, Xinyu Zheng1,4 1. Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, People’s Republic of China 2. Department of anesthesiology, The Shengjing Hospital of China Medical University, Shenyang, Liaoning 110001, People’s Republic of China 3. Department of Breast Surgery, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People’s Republic of China 4. Lab 1, Cancer Institute, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, People’s Republic of China Corresponding author: Prof. Xinyu Zheng, Department of Breast Surgery, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang City, Liaoning Province, 110001, People’s Republic of China. Fax number: 0086 24 83282741 Telephone number: 0086 24 83282741 E-mail: [email protected] © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.08.26; Accepted: 2019.09.19; Published: 2019.10.18 Abstract Retinoic acid-induced 14 (RAI14) is involved in the development of different tumor types, however, its expression and biological function in breast cancer are yet unknown.
    [Show full text]
  • Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis
    Published OnlineFirst January 26, 2010; DOI: 10.1158/0008-5472.CAN-09-2703 Published Online First on January 26, 2010 as 10.1158/0008-5472.CAN-09-2703 Integrated Systems and Technologies Cancer Research Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis Martin Dutertre1, Magali Lacroix-Triki3,4,5, Keltouma Driouch6, Pierre de la Grange2, Lise Gratadou1, Samantha Beck3,4,5, Stefania Millevoi3,4,5, Jamal Tazi7, Rosette Lidereau6, Stephan Vagner3,4,5, and Didier Auboeuf1 Abstract In the field of bioinformatics, exon profiling is a developing area of disease-associated transcriptome anal- ysis. In this study, we performed a microarray-based transcriptome analysis at the single exon level in mouse 4T1 primary mammary tumors with different metastatic capabilities. A novel bioinformatics platform was developed that identified 679 genes with differentially expressed exons in 4T1 tumors, many of which were involved in cell morphology and movement. Of 152 alternative exons tested by reverse transcription-PCR, 97 were validated as differentially expressed in primary tumors with different metastatic capability. This anal- ysis revealed candidate progression genes, hinting at variations in protein functions by alternate exon usage. In a parallel effort, we developed a novel exon-based clustering analysis and identified alternative exons in tumor transcriptomes that were associated with dissemination of primary tumor cells to sites of pulmonary metastasis. This analysis also revealed that the splicing events identified by comparing primary tumors were not aberrant events. Lastly, we found that a subset of differentially spliced variant transcripts identified in the murine model was associated with poor prognosis in a large clinical cohort of patients with breast cancer.
    [Show full text]
  • Confirmation of Pathogenic Mechanisms by SARS-Cov-2–Host
    Messina et al. Cell Death and Disease (2021) 12:788 https://doi.org/10.1038/s41419-021-03881-8 Cell Death & Disease ARTICLE Open Access Looking for pathways related to COVID-19: confirmation of pathogenic mechanisms by SARS-CoV-2–host interactome Francesco Messina 1, Emanuela Giombini1, Chiara Montaldo1, Ashish Arunkumar Sharma2, Antonio Zoccoli3, Rafick-Pierre Sekaly2, Franco Locatelli4, Alimuddin Zumla5, Markus Maeurer6,7, Maria R. Capobianchi1, Francesco Nicola Lauria1 and Giuseppe Ippolito 1 Abstract In the last months, many studies have clearly described several mechanisms of SARS-CoV-2 infection at cell and tissue level, but the mechanisms of interaction between host and SARS-CoV-2, determining the grade of COVID-19 severity, are still unknown. We provide a network analysis on protein–protein interactions (PPI) between viral and host proteins to better identify host biological responses, induced by both whole proteome of SARS-CoV-2 and specific viral proteins. A host-virus interactome was inferred, applying an explorative algorithm (Random Walk with Restart, RWR) triggered by 28 proteins of SARS-CoV-2. The analysis of PPI allowed to estimate the distribution of SARS-CoV-2 proteins in the host cell. Interactome built around one single viral protein allowed to define a different response, underlining as ORF8 and ORF3a modulated cardiovascular diseases and pro-inflammatory pathways, respectively. Finally, the network-based approach highlighted a possible direct action of ORF3a and NS7b to enhancing Bradykinin Storm. This network-based representation of SARS-CoV-2 infection could be a framework for pathogenic evaluation of specific 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; clinical outcomes.
    [Show full text]
  • Functional Analysis of Structural Variation in the 2D and 3D Human Genome
    FUNCTIONAL ANALYSIS OF STRUCTURAL VARIATION IN THE 2D AND 3D HUMAN GENOME by Conor Mitchell Liam Nodzak A dissertation submitted to the faculty of The University of North Carolina at Charlotte in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Bioinformatics and Computational Biology Charlotte 2019 Approved by: Dr. Xinghua Mindy Shi Dr. Rebekah Rogers Dr. Jun-tao Guo Dr. Adam Reitzel ii c 2019 Conor Mitchell Liam Nodzak ALL RIGHTS RESERVED iii ABSTRACT CONOR MITCHELL LIAM NODZAK. Functional analysis of structural variation in the 2D and 3D human genome. (Under the direction of DR. XINGHUA MINDY SHI) The human genome consists of over 3 billion nucleotides that have an average distance of 3.4 Angstroms between each base, which equates to over two meters of DNA contained within the 125 µm3 volume diploid cell nuclei. The dense compaction of chromatin by the supercoiling of DNA forms distinct architectural modules called topologically associated domains (TADs), which keep protein-coding genes, noncoding RNAs and epigenetic regulatory elements in close nuclear space. It has recently been shown that these conserved chromatin structures may contribute to tissue-specific gene expression through the encapsulation of genes and cis-regulatory elements, and mutations that affect TADs can lead to developmental disorders and some forms of cancer. At the population-level, genomic structural variation contributes more to cumulative genetic difference than any other class of mutation, yet much remains to be studied as to how structural variation affects TADs. Here, we study the func- tional effects of structural variants (SVs) through the analysis of chromatin topology and gene activity for three trio families sampled from genetically diverse popula- tions from the Human Genome Structural Variation Consortium.
    [Show full text]